REG - Hikma Pharmaceutical - Block listing Interim Review

Hikma PharmaceuticalsAnnouncement

02/10/2023 10:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231002:nRSB3526Oa&default-theme=true

RNS Number : 3526O  Hikma Pharmaceuticals Plc  02 October 2023

Hikma Pharmaceuticals PLC

 

 

 

 

Block Listing Six Monthly Return

 

Date: 2 October 2023

 

 Name of applicant:                                                            Hikma Pharmaceuticals PLC
 Name of scheme:                                                               Hikma Pharmaceuticals PLC 2018 Management Incentive Plan ("2018 MIP") and
                                                                               Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan ("EIP") (together "the
                                                                               Plans")
 Period of return                                                              From: 1 April 2023           To:                          30 September 2023
 Balance of unallotted securities under scheme(s) from previous return:        The Plans: 1,497,913 Ordinary Shares of 10 pence
 Plus:  The amount by which the block scheme(s) has been increased since the   The Plans: 0 Ordinary Shares of 10 pence
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period     2018 MIP: 438 Ordinary Shares of 10 pence
 (see LR3.5.7G):

                                                                               EIP: 378,765 Ordinary Shares of 10 pence
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:    The Plans: 1,118,710 Ordinary Shares of 10 pence

 

 Name of contact:              Hussein Arkhagha
 Telephone number of contact:  +44(0)20 7399 2760

 

LEI: 549300BNS685UXH4JI75

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRUPGPGUUPWUBP